Pfizer has sent the full results of its final Covid-19 vaccine trial to drugs watchdogs in Britain, Europe and the US as the world inches closer to getting its hands on a jab.
The American pharmaceutical giant – most famous for making Viagra – claims its vaccine is 95 per cent effective and works in older people most vulnerable to Covid.
Regulators will now pore over data from the phase three clinical trial to make sure the study was up to scratch and the jab is safe to dish out en masse.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have been doing a ‘rolling review’ of the vaccine.
This means the approval process could be wrapped up in a matter of days and the high risk people could start getting their hands on it by the end of the year.
Britain has already pre-ordered 40million doses of the vaccine and could be set to get 10m of those next month, with the NHS on standby to start dishing it out on December 1.
Final trial results of the jab by Pfizer and BioNTech, the German firm involved in making the jab, showed that only eight people out more than 20,000 who got the vaccine caught coronavirus compared to 162 who were given a fake jab. A total of 10 people got severe Covid-19, one of whom had been given the real vaccine.
Pfizer and BioNTech today upgraded the estimate of how effective their vaccine is, taking it from 90 per cent in interim clinical trial results to 95 per cent today (stock image)